New drug shows promise for tough bladder cancer?

NCT ID NCT02657486

Completed Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a drug called BGJ398 in 4 people with a type of bladder cancer that stays in the bladder lining but keeps coming back after standard treatment. The drug targets tumors with a specific genetic change (FGFR3 mutation or fusion). The main goal was to see if the drug could make the tumor disappear completely after 7 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGJ398 (a targeted drug that blocks FGFR3 mutations or gene fusions)
What this could lead to: If it works, this could point toward a new treatment option for bladder cancer patients whose tumors have specific genetic changes.
What could go wrong: This was a very small pilot study with only 4 participants, so results may not apply to most patients. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER NON-MUSCLE-INVASIVE UROTHELIAL CARCINOMA

Contacts and locations

Show contact details

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.